Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of MST-188 (Purified Poloxamer 188) Injection in Subjects With Sickle Cell Disease Experiencing Vaso Occlusive Crisis

drug protocol number
MST-188-01
drug sponsor
Mast Therapeutics
drug study
Purified Poloxamer 188
drug trial site
KKUH
drug status
Ongoing
drug phase